The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Masimo (MASI - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Masimo is one of 867 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. MASI is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for MASI's full-year earnings has moved 0.96% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, MASI has moved about 41.10% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 3.26% on a year-to-date basis. This shows that Masimo is outperforming its peers so far this year.
To break things down more, MASI belongs to the Medical - Instruments industry, a group that includes 96 individual companies and currently sits at #79 in the Zacks Industry Rank. On average, this group has gained an average of 14.54% so far this year, meaning that MASI is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on MASI as it attempts to continue its solid performance.